Axsome Therapeutics, Inc. (AXSM) Cash Flow Statement

The consistently positive OCF/NI ratios, despite negative operating cash flow, indicate that non-cash charges, principally stock-based compensation of $22M to $27M per quarter, are absorbing a large share of the reported loss. This suggests that a meaningful portion of the economic cost is being paid in equity rather than cash. Investors should monitor whether the gap closes as SBC plateaus, since a rising cash cost base would otherwise widen the burn.

The trajectory points to a structural improvement in cash generation, though the quarterly pattern is volatile, with working capital swings of up to $24.7M distorting individual readings. The Q3 2025 positive FCF appears to have been driven partly by favorable working capital timing rather than durable operating strength. Sustained positive FCF would require the margin improvement to persist through several consecutive quarters, which the data does not yet confirm.

Such minimal capital intensity is consistent with an outsourced-manufacturing, small-molecule pharmaceutical model, where the primary investment is in commercial and R&D personnel rather than plant or equipment. Depreciation and amortization of $1.7M to $3.1M per quarter likely reflects intangible amortization rather than maintenance of physical assets. Because reinvestment needs are low, the cash constraint is driven by operating expense rather than capital spending.

Large swings in working capital suggest that receivable collection timing and inventory stocking, particularly during the Auvelity launch, are materially affecting reported cash flow. Positive working capital inflows in several quarters may reflect collection of earlier receivables rather than sustainable efficiency gains. Analysts should treat individual quarterly FCF readings with caution and focus on the multi-quarter trend when assessing cash generation.